209 related articles for article (PubMed ID: 26348911)
41. Differential effects of the β-adrenoceptor blockers carvedilol and metoprolol on SQT1- and SQT2-mutant channels.
Bodi I; Franke G; Pantulu ND; Wu K; Perez-Feliz S; Bode C; Zehender M; zur Hausen A; Brunner M; Odening KE
J Cardiovasc Electrophysiol; 2013 Oct; 24(10):1163-71. PubMed ID: 23718892
[TBL] [Abstract][Full Text] [Related]
42. [Effect of carvedilol and Radix astragali on ryanodine receptor in heart failure in mice].
Li R; Zhang Q; Yi QJ
Zhonghua Er Ke Za Zhi; 2011 Jun; 49(6):433-8. PubMed ID: 21924056
[TBL] [Abstract][Full Text] [Related]
43. The cardiac ryanodine receptor, but not sarcoplasmic reticulum Ca
Sun B; Wei J; Zhong X; Guo W; Yao J; Wang R; Vallmitjana A; Benitez R; Hove-Madsen L; Chen SRW
J Biol Chem; 2018 Aug; 293(35):13650-13661. PubMed ID: 29986885
[TBL] [Abstract][Full Text] [Related]
44. Scavenging free radicals by low-dose carvedilol prevents redox-dependent Ca2+ leak via stabilization of ryanodine receptor in heart failure.
Mochizuki M; Yano M; Oda T; Tateishi H; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
J Am Coll Cardiol; 2007 Apr; 49(16):1722-32. PubMed ID: 17448375
[TBL] [Abstract][Full Text] [Related]
45. Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction.
Naccarelli GV; Lukas MA
Clin Cardiol; 2005 Apr; 28(4):165-73. PubMed ID: 15869048
[TBL] [Abstract][Full Text] [Related]
46. TRIC-A Channel Maintains Store Calcium Handling by Interacting With Type 2 Ryanodine Receptor in Cardiac Muscle.
Zhou X; Park KH; Yamazaki D; Lin PH; Nishi M; Ma Z; Qiu L; Murayama T; Zou X; Takeshima H; Zhou J; Ma J
Circ Res; 2020 Feb; 126(4):417-435. PubMed ID: 31805819
[TBL] [Abstract][Full Text] [Related]
47. Ryanodine receptor mutations associated with stress-induced ventricular tachycardia mediate increased calcium release in stimulated cardiomyocytes.
George CH; Higgs GV; Lai FA
Circ Res; 2003 Sep; 93(6):531-40. PubMed ID: 12919952
[TBL] [Abstract][Full Text] [Related]
48. CPVT-associated cardiac ryanodine receptor mutation G357S with reduced penetrance impairs Ca2+ release termination and diminishes protein expression.
Liu Y; Wei J; Wong King Yuen SM; Sun B; Tang Y; Wang R; Van Petegem F; Chen SRW
PLoS One; 2017; 12(9):e0184177. PubMed ID: 28961276
[TBL] [Abstract][Full Text] [Related]
49. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
50. Enhanced store overload-induced Ca2+ release and channel sensitivity to luminal Ca2+ activation are common defects of RyR2 mutations linked to ventricular tachycardia and sudden death.
Jiang D; Wang R; Xiao B; Kong H; Hunt DJ; Choi P; Zhang L; Chen SR
Circ Res; 2005 Nov; 97(11):1173-81. PubMed ID: 16239587
[TBL] [Abstract][Full Text] [Related]
51. Exercise training prevents ventricular tachycardia in CPVT1 due to reduced CaMKII-dependent arrhythmogenic Ca2+ release.
Manotheepan R; Danielsen TK; Sadredini M; Anderson ME; Carlson CR; Lehnart SE; Sjaastad I; Stokke MK
Cardiovasc Res; 2016 Aug; 111(3):295-306. PubMed ID: 27161030
[TBL] [Abstract][Full Text] [Related]
52. Slowed depolarization and irregular repolarization in catecholaminergic polymorphic ventricular tachycardia: a study from cellular Ca2+ transients and action potentials to clinical monophasic action potentials and electrocardiography.
Paavola J; Väänänen H; Larsson K; Penttinen K; Toivonen L; Kontula K; Laine M; Aalto-Setälä K; Swan H; Viitasalo M
Europace; 2016 Oct; 18(10):1599-1607. PubMed ID: 26705554
[TBL] [Abstract][Full Text] [Related]
53. The CPVT-associated RyR2 mutation G230C enhances store overload-induced Ca2+ release and destabilizes the N-terminal domains.
Liu Y; Kimlicka L; Hiess F; Tian X; Wang R; Zhang L; Jones PP; Van Petegem F; Chen SR
Biochem J; 2013 Aug; 454(1):123-31. PubMed ID: 23746327
[TBL] [Abstract][Full Text] [Related]
54. Targeting ryanodine receptors for anti-arrhythmic therapy.
McCauley MD; Wehrens XH
Acta Pharmacol Sin; 2011 Jun; 32(6):749-57. PubMed ID: 21642946
[TBL] [Abstract][Full Text] [Related]
55. Catecholaminergic polymorphic ventricular tachycardia is caused by mutation-linked defective conformational regulation of the ryanodine receptor.
Uchinoumi H; Yano M; Suetomi T; Ono M; Xu X; Tateishi H; Oda T; Okuda S; Doi M; Kobayashi S; Yamamoto T; Ikeda Y; Ohkusa T; Ikemoto N; Matsuzaki M
Circ Res; 2010 Apr; 106(8):1413-24. PubMed ID: 20224043
[TBL] [Abstract][Full Text] [Related]
56. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
57. Arrhythmogenic Calmodulin Mutations Affect the Activation and Termination of Cardiac Ryanodine Receptor-mediated Ca2+ Release.
Søndergaard MT; Tian X; Liu Y; Wang R; Chazin WJ; Chen SR; Overgaard MT
J Biol Chem; 2015 Oct; 290(43):26151-62. PubMed ID: 26309258
[TBL] [Abstract][Full Text] [Related]
58. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy.
Kannankeril PJ; Mitchell BM; Goonasekera SA; Chelu MG; Zhang W; Sood S; Kearney DL; Danila CI; De Biasi M; Wehrens XH; Pautler RG; Roden DM; Taffet GE; Dirksen RT; Anderson ME; Hamilton SL
Proc Natl Acad Sci U S A; 2006 Aug; 103(32):12179-84. PubMed ID: 16873551
[TBL] [Abstract][Full Text] [Related]
59. Oxidation of ryanodine receptor after ischemia-reperfusion increases propensity of Ca
Bovo E; Mazurek SR; Zima AV
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H1032-H1040. PubMed ID: 30028204
[TBL] [Abstract][Full Text] [Related]
60. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
